Na+ and the substrate permeation pathway in dopamine transporters

European Journal of Pharmacology

Volumn 479, Issue 1-3, 2003, Pages 213-221

  Chen, Nianhang ^a,b   Reith, Maarten E A ^a,b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Access model; Cation; DAT (dopamine transporter); Dopamine recognition; Na+

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLALLYL)PIPERAZINE; AMINO ACID; ASPARTIC ACID DERIVATIVE; COCAINE; COTRANSPORTER; DOPAMINE; DOPAMINE TRANSPORTER; HYDROGEN; MUTANT PROTEIN; SODIUM ION; TRYPTOPHAN DERIVATIVE;

AMINE TRANSPORT; AMINO ACID SEQUENCE; BINDING SITE; CELL FUNCTION; CELL MEMBRANE PERMEABILITY; CELL TRANSPORT; EXPERIMENTAL MODEL; HUMAN; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 0242659428     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.08.070     Document Type: Article

References (57)

1. Amara S.G., Sonders M.S. Neurotransmitter transporters as molecular targets for addictive drugs. Drug Alcohol Depend. 51:1998;87-96.
2. + dependence of the neuronal transport of dopamine. J. Neurochem. 59:1992;1795-1804.
3. Amejdki-Chab N., Costentin J., Bonnet J.-J. Kinetic analysis of the chloride dependence of the neuronal uptake of dopamine and effect of anions on the ability of substrates to compete with the binding of the dopamine uptake inhibitor GBR 12783. J. Neurochem. 58:1992;793-800.
4. Barker E.L., Moore K.R., Rakhshan F., Blakely R.D. Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter. J. Neurosci. 19:1999;4705-4717.
5. Berfield J.L., Wang L.C., Reith M.E.A. Which form of dopamine is the substrate for the human dopamine transporter: the cationic or the uncharged species? J. Biol. Chem. 274:1999;4876-4882.
6. Bönisch H. Transport and drug binding kinetics in membrane vesicle preparation. Methods Enzymol. 296:1998;259-278.
7. 3H]GBR12783 to a site associated with the dopamine uptake carrier. J. Neurochem. 50:1988;759-765.
8. Carlsson A., Jonason J., Lindqvist M., Fuxe K. Demonstration of extraneuronal 5-hydroxytryptamine accumulation in brain following membrane-pump blockade by chlorimipramine. Brain Res. 12:1969;456-460.
9. 125I]iodophenyl)tropane-2 β-carboxylic acid isopropyl ester to the dopamine transporter. J. Neurochem. 68:1997;1968-1981.
10. Chen N.H., Wang Y.L., Reith M.E.A. Binding of the [125I]3 beta-(iodophenyl)tropan-2 beta-carboxylic acid isopropyl ester to the dopamine transporter at a physiologically relevant temperature: mutually exclusive binding and different ionic requirements for various uptake blockers and substrates. Synapse. 25:1997;155-162.
11. Chen N., Trowbridge C.G., Justice J.B. Jr. Voltammetric studies on mechanisms of dopamine efflux in the presence of substrates and cocaine from cells expressing human norepinephrine transporter. J. Neurochem. 71:1998;653-665.
12. Chen N., Trowbridge C.G., Justice J.B. Jr. Cationic modulation of human dopamine transporter: dopamine uptake and inhibition of uptake. J. Pharmacol. Exp. Ther. 290:1999;940-949.
13. Chen N., Vaughan R.A., Reith M.E.A. The role of conserved tryptophan and acidic residues in the human dopamine transporter as characterized by site-directed mutagenesis. J. Neurochem. 77:2001;1116-1127.
14. Chen N., Sun L., Reith M.E.A. Cationic interactions at the human dopamine transporter reveal binding conformations for dopamine distinguishable from those for the cocaine analog 2β-carbomethoxy-3β-(4-fluorophenyl) tropane. J. Neurochem. 81:2002;1383-1393.
15. + stimulates binding of dopamine to the dopamine transporter in cells but not in cell-free preparations. J. Neurochem. 86:2003;678-686.
16. Corera A.T., Costentin J., Bonnet J.-J. Binding of uptake blockers to the neuronal dopamine transporter: further investigation about cationic and anionic requirements. Naunyn-Schmiedeberg's Arch. Pharmacol. 362:2000;213-221.
17. Coyle J.T., Snyder S.H. Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action. Science. 166:1969;899-901.
18. Descarries L., Seguela P., Watkins K.C. Nonjunctional relationships of monoamine axon terminals in the cerebral cortex of adult rat. Fuxe K., Agnati L.F. Volume Transmission in the Brain: Novel Mechanisms for Neural Transmission. 1991;53-62 Raven Press, New York.
19. Earles C., Schenk J.O. Multisubstrate mechanism for the inward transport of dopamine by the human dopamine transporter expressed in HEK cells and its inhibition by cocaine. Synapse. 33:1999;230-238.
20. Forlani G., Bossi E., Ghirardelli R., Giovannardi S., Binda F., Bonadiman L., Ielmini L., Peres A. Mutation of K448 in the external loop 5 of rat GABA transporter rGAT1 induces pH sensitivity and alters substrate interactions. J. Physiol. 536.2:2001;479-494.
21. Garris P.A., Wightman R.M. Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study. J. Neurosci. 14:1994;442-450.
22. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev. 21:2000;90-113.
23. Giros B., Mestikawy S.E., Godinot N., Zheng K., Han H., Yang-Feng T., Caron M.G. Cloning, Pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol. Pharmacol. 42:1992;383-390.
24. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 379:1996;606-612.
25. Gu H., Wall S., Rudnick G. Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J. Biol. Chem. 269:1994;7124-7130.
26. 3H]GBR12783 binding to the dopamine neuronal carrier. Eur. J. Pharmacol. 301:1996;195-202.
27. Iversen L.L. Role of transmitter uptake mechanisms in synaptic neurotransmission. Br. J. Pharmacol. 41:1971;571-591.
28. Jones S.R., Gainetdinov R.R., Jaber M., Giros B., Wightman R.M., Caron M.G. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc. Natl. Acad. Sci. U. S. A. 95:1998;4029-4034.
29. + and methanethiosulfonate reagents. J. Biol. Chem. 276:2001;4038-4045.
30. +-dependent mechanism. J. Biol. Chem. 278:2003;12070-12077.
31. Kilty J.E., Lorang D., Amara S.G. Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science. 254:1991;578-579.
32. Kumpf R.A., Dougherty D.A. A mechanism for ion selectivity in potassium channels: computational studies of cation-pi interactions. Science. 261:1993;1708-1710.
33. 3H]WIN 35,428 to the human dopamine transporter. J. Neurochem. 72:1999;1095-1109.
34. - with the binding of amphetamine, octopamine, and tyramine to the human dopamine transporter. J. Neurochem. 74:2000;1538-1552.
35. Li M., Farley R.A., Lester H.A. An intermediate state of the gamma-aminobutyric acid transporter GAT1 revealed by simultaneous voltage clamp and fluorescence. J. Gen. Physiol. 115:2000;491-508.
36. + required for the binding of dopamine, amphetamine, tyramine, and octopamine to the human dopamine transporter? Naunyn-Schmiedeberg's Arch. Pharmacol. 365:2002;303-311.
37. Mager S., Kleinberger-Doron N., Keshet G.I., Davidson N., Kanner B.I., Lester H.A. Ion binding and permeation at the GABA transporter GAT1. J. Neurosci. 16:1996;5405-5414.
38. Martin S., Botto J.M., Vincent J.P., Mazella J. Pivotal role of an aspartate residue in sodium sensitivity and coupling to G proteins of neurotensin receptors. Mol. Pharmacol. 55:1999;210-215.
39. McElvain J.S., Schenk J.O. A multisubstrate mechanism of striatal dopamine uptake and its inhibition by cocaine. Biochem. Pharmacol. 43:1992;2189-2199.
40. Miller C. Potassium selectivity in proteins: oxygen cage or in the F ace? Science. 261:1993;1692-1693.
41. Millier G.W., Gainetdinov R.R., Levey A.I., Caron M.G. Dopamine transporters and neuronal injury. Trends Pharmacol. Sci. 20:1999;424-429.
42. Penado K.M., Rudnick G., Stephan M.M. Critical amino acid residues in transmembrane span 7 of the serotonin transporter identified by random mutagenesis. J. Biol. Chem. 273:1998;28098-28106.
43. Pifl C., Singer E.A. Ion dependence of carrier-mediated release in dopamine or norepinephrine transporter-transfected cells questions the hypothesis of facilitated exchange diffusion. Mol. Pharmacol. 56:1999;1047-1054.
44. - of cocaine sensitive carrier-mediated efflux of amines from cells transfected with the cloned human dopamine transporters. Br. J. Pharmacol. 121:1997;205-212.
45. Poolman B., Knol J., van der Does C., Henderson P.J., Liang W.J., Leblanc G., Pourcher T., Mus-Veteau I. Cation and sugar selectivity determinants in a novel family of transport proteins. Mol. Microbiol. 19:1996;911-922.
46. 3H]tropane to the dopamine uptake carrier. J. Neurochem. 61:1993;167-177.
47. Rudnick G. Mechanisms of biogenic amine transport. Reith M.E.A. Neurotransmitter Transporter: Structure, Function, and Regulation. 2002;25-52 Humana Press, Totowa, NJ.
48. Scholze P., Zwach J., Kattinger A., Pifl C., Singer E.A., Sitte H.H. Transporter-mediated release: a superfusion study on human embryonic kidney cells stable expressing the human serotonin transporter. J. Pharmacol. Exp. Ther. 293:2000;870-878.
49. Shaskan E.G., Snyder S.H. Kinetics of serotonin accumulation into slices from rat brain: relationship to catecholamine uptake. J. Pharmacol. Exp. Ther. 175:1970;404-418.
50. Shimada S., Kitayama S., Lin C.-L., Patel A., Nanthakumar E., Gergor P., Kuhar M., Uhl G. Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science. 25:1991;576-578.
51. Siesjo B.K., von Hanwehr R., Nergelius G., Nevander G., Ingvar M. Extra- and intracellular pH in the brain during seizures and in the recovery period following the arrest of seizure activity. J. Cereb. Blood Flow Metab. 5:1985;47-57.
52. Sonders M.S., Zhu S.J., Zahniser N.R., Kavanaugh M.P., Amara S.G. Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J. Neurosci. 17:1997;960-974.
53. --dependence of dopamine transport. Mol. Pharmacol. 58:2000;1404-1411.
54. Tatsumi M., Groshan K., Blakely R.D., Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. 340:1997;249-258.
55. Vandenbergh D.J., Persico A.M., Uhl G.R. A human dopamine transporter cDNA predicts reduced glycosylation, display a novel repetitive element and provides racially-dimorphic Taq I RFLPs. Mol. Brain Res. 15:1992;161-166.
56. Whitby L.G., Hertting G., Axelrod J. Effect of cocaine on the disposition of noradrenaline labeled with tritium. Nature. 187:1960;604-605.
57. Zoli M., Jansson A., Sykova E., Agnati L.F., Fuxe K. Volume transmission in the CNS and its relevance for neuropsychopharmacology. Trends Pharmacol. Sci. 20:1999;142-150.